Which closed-end funds own Vertex Pharmaceuticals Inc?
16 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $113M. Security type: common equity. Country: United States. CUSIP 92532F100 · ISIN US92532F1003 · ticker VRTX.
Holdings are historical filings (report dates May 29, 2026 – Jul 31, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| BME BlackRock Health Sciences Trust | Healthcare | 2.77% | $15.9M | 31,983 sh | $573M | 3.7% discount | Jun 30, 2026 |
| BMEZ BlackRock Health Sciences Term Trust | Healthcare | 0.96% | $10.4M | 20,900 sh | $1.1B | NAV unavailable | Jun 30, 2026 |
| ADX Adams Diversified Equity Fund | U.S. Equity | 0.71% | $23.5M | 47,300 sh | $3.3B | 3.4% discount | Jun 30, 2026 |
| GRX Gabelli Healthcare & WellnessRx Trust | Healthcare | 0.70% | $1.6M | 3,200 sh | $228M | NAV unavailable | Jun 30, 2026 |
| USA Liberty All Star Equity Fund | U.S. Equity | 0.60% | $12.2M | 24,576 sh | $2B | 12.8% discount | Jun 30, 2026 |
| ECAT BlackRock ESG Capital Allocation Term Trust | U.S. Equity | 0.41% | $6.9M | 13,929 sh | $1.7B | NAV unavailable | Jun 30, 2026 |
| CLM Cornerstone Strategic Investment Fund | Multi-Asset | 0.40% | $8M | 16,203 sh | $2B | 2.6% premium | Jun 30, 2026 |
| CRF Cornerstone Total Return Fund | Multi-Asset | 0.40% | $4.3M | 8,557 sh | $1.1B | 0.3% discount | Jun 30, 2026 |
| CSQ Calamos Strategic Total Return Fund | Multi-Asset | 0.29% | $14.1M | 29,645 sh | $4.9B | 9.4% discount | Jul 31, 2026 |
| HQL abrdn Life Sciences Investors | Healthcare | 0.27% | $1.9M | 3,797 sh | $690M | 3.5% discount | Jun 30, 2026 |
| TY Tri-Continental Corp | U.S. Equity | 0.25% | $5.2M | 10,548 sh | $2.1B | NAV unavailable | Jun 30, 2026 |
| BCAT BlackRock Capital Allocation Term Trust | U.S. Equity | 0.25% | $4.2M | 8,439 sh | $1.7B | NAV unavailable | Jun 30, 2026 |
| HQH abrdn Healthcare Investors | Healthcare | 0.25% | $3.4M | 6,786 sh | $1.4B | 7.5% discount | Jun 30, 2026 |
| GDV Gabelli Dividend & Income Trust | U.S. Equity | 0.06% | $2M | 4,000 sh | $3.4B | 13.2% discount | Jun 30, 2026 |
| GOF Guggenheim Strategic Opportunities Fund | Multi-Asset | 0.00% | $16.6K | 37 sh | $2.8B | 12.9% discount | May 29, 2026 |
| BRW Saba Capital Income & Opportunities Fund | U.S. Equity | -0.05% | $-163K | -342 sh | $351M | 17.8% discount | Jul 31, 2026 |
16 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Also listed in filings as: VERTEX PHARMACEUTICALS INC; Vertex Pharmaceuticals Incorporated.
Issuer-level search for “VRTX” → · Compare two funds’ portfolios →